勃起功能障碍（ED）深刻地影响生活质量。 ED的肾移植受者的患病率是高达50％到60％的报道。我们评估的伐地那非的疗效和安全性在这些ED患者以及其对移植肾功能和cylosporine或他克莫司浓度的影响。三十九收件人与ED和血清肌酐值<2 mg/dL were treated with 伐地那非. ED was assessed using the self-administered International Index of Erectile Function (IIEF). ED was diagnosed by using penile color-Doppler ultrasonography and intracavernosal injection. Vardenafil efficacy was assessed by readministering the IIEF questionnaire after 4 weeks of therapy. Serum creatinine levels, creatinine clearances, and cyclosporine/tacrolimus concentrations were measured before and after 伐地那非 therapy. Twenty-one recipients with ED served as placebo controls and 15 without ED as another control group. The IIEF scores improved from 12.80 ± 3.5 to 26.46 ± 2.4 in 伐地那非-treated patients with ED ( P < .001). Renal function and cyclosporine/tacrolimus concentrations did not change with 伐地那非 therapy. Side effects were observed in 7 (18%) patients: headache in three, palpitations in one, flushing in two, and dyspepsia in one. This study demonstrated that ED improved with 伐地那非 in renal transplant recipients with ED. For 4 weeks 伐地那非 therapy was free of side effects. Renal function tests did not change. Also, no dose change in immunosuppressive drugs was required during 4 weeks of verdanafil therapy.
药道全球直邮药房 - 印度，孟加拉海外直邮网上药房
- WhatsApp 沟通